{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:48:25Z","timestamp":1791247705017,"version":"4.1.0"},"reference-count":44,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,1,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p> To investigate the impact of histologic type invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) on response to primary chemotherapy (PC) and long-term outcome. <\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p> The study included 1,034 patients with stage II and III breast cancer who participated in six clinical trials of PC at our institution between 1985 and 2002. One hundred twenty-two patients (12%) had ILC and 912 (88%) had IDC. All patients received anthracycline-based PC, and 346 patients (33.5%) also received a taxane as part of PC. Pathologic complete response (pCR) was defined as no evidence of invasive disease in the breast and axillary lymph nodes. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p> The median patient age was 48 years (range, 18 to 79 years). Patients with ILC tended to be older (median age, 53 years v 47 years for patients with IDC) and have more hormone-receptor\u2013positive tumors (92% v 62%; P &lt; .001), lower nuclear grade (nuclear grade 3, 16% v 56%; P &lt; .001), and higher stage at diagnosis (10% v 0% with stage IIIB or IIIC disease; P &lt; .001). Patients with ILC were less likely to have a pCR (3% v 15%; P &lt; .001) and had a larger number of involved axillary lymph nodes (41% v 26% had &gt; 3 involved nodes; P = .001). At a median follow-up time of 70 months, ILC patients tended to have longer recurrence-free survival (P = .004) and overall survival (P = .001). <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p> ILC is characterized by lower rates of pathologic response to PC but better long-term outcomes compared to IDC. pCR might not be a prognostic indicator for this group of patients. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.03.111","type":"journal-article","created":{"date-parts":[[2004,12,30]],"date-time":"2004-12-30T03:31:33Z","timestamp":1104377493000},"page":"41-48","source":"Crossref","is-referenced-by-count":359,"title":["Invasive Lobular Carcinoma Classic Type: Response to Primary Chemotherapy and Survival Outcomes"],"prefix":"10.1200","volume":"23","author":[{"given":"Massimo","family":"Cristofanilli","sequence":"first","affiliation":[{"name":"From the Departments of Breast Medical Oncology, Pathology, Biostatistics, Surgical Oncology, and Radiotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Gonzalez-Angulo","sequence":"additional","affiliation":[{"name":"From the Departments of Breast Medical Oncology, Pathology, Biostatistics, Surgical Oncology, and Radiotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nour","family":"Sneige","sequence":"additional","affiliation":[{"name":"From the Departments of Breast Medical Oncology, Pathology, Biostatistics, Surgical Oncology, and Radiotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Wan","family":"Kau","sequence":"additional","affiliation":[{"name":"From the Departments of Breast Medical Oncology, Pathology, Biostatistics, Surgical Oncology, and Radiotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Broglio","sequence":"additional","affiliation":[{"name":"From the Departments of Breast Medical Oncology, Pathology, Biostatistics, Surgical Oncology, and Radiotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Theriault","sequence":"additional","affiliation":[{"name":"From the Departments of Breast Medical Oncology, Pathology, Biostatistics, Surgical Oncology, and Radiotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[{"name":"From the Departments of Breast Medical Oncology, Pathology, Biostatistics, Surgical Oncology, and Radiotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman U.","family":"Buzdar","sequence":"additional","affiliation":[{"name":"From the Departments of Breast Medical Oncology, Pathology, Biostatistics, Surgical Oncology, and Radiotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Kuerer","sequence":"additional","affiliation":[{"name":"From the Departments of Breast Medical Oncology, Pathology, Biostatistics, Surgical Oncology, and Radiotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Buccholz","sequence":"additional","affiliation":[{"name":"From the Departments of Breast Medical Oncology, Pathology, Biostatistics, Surgical Oncology, and Radiotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel N.","family":"Hortobagyi","sequence":"additional","affiliation":[{"name":"From the Departments of Breast Medical Oncology, Pathology, Biostatistics, Surgical Oncology, and Radiotherapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/78.6.806"},{"key":"R2","unstructured":"Wellings SR, Jensen HM, Marcum RG: An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst 55:231,1975-273,"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197507)36:1<1::AID-CNCR2820360102>3.0.CO;2-4"},{"key":"R4","unstructured":"Wheeler JE, Enterline HT: Lobular carcinoma of the breast in situ and infiltrating. Pathol Annu 11:161,1976-188,"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1979.tb03029.x"},{"key":"R6","unstructured":"Foote FWJ, Stewart FW: Histologic classification of carcinoma of the breast. Surgery 19:74,1946-99,"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1982.tb02712.x"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1989.323"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1984.135"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1002\/jso.2930480106"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(75)80099-2"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1186\/bcr508"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9896(199712)183:4<404::AID-PATH1148>3.0.CO;2-9"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.191367098"},{"key":"R16","unstructured":"Korkola JE, DeVries S, Fridlyand J, et al: Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 63:7167,2003-7175,"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900701)66:1<102::AID-CNCR2820660119>3.0.CO;2-5"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1997.540"},{"key":"R19","unstructured":"Rouzier RD, Youmsi E, Delaloge S, et al: Predictors of breast-conserving surgery after epirubicin-based neoadjuvant chemotherapy for large breast carcinoma. Proc Am Soc Clin Oncol 22:38a,2003,  (abstr 151)"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2672"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1304"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.2.460"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3412"},{"key":"R24","unstructured":"Green MC, Buzdar AU, Smith T, et al: Weekly paclitaxel followed by FAC in the neo-adjuvant setting provides improved pathologic complete remission rates compared to standard paclitaxel followed by FAC therapy-preliminary results of an ongoing prospective randomized trial. Proc Am Soc Clin Oncol 20:33a,2001,  (abstr 129)"},{"key":"R25","unstructured":"Dhingra K, Esparza-Guerra L, Valero V, et al: A phase III randomized trial of dose-intensive neoadjuvant 5FU, doxorubicin, cyclophosphamide (FAC) with G-CSF (filgrastin) in locally advanced breast cancer (LABC): Efficacy and safety data. Proc Amer Soc Clin Oncol 18:74a,1999,  (abstr 278)"},{"key":"R26","unstructured":"Hortobagyi GN, Holmes FA, Frye D, et al: Comparison of two adjuvant chemotherapy programs for locally advanced breast cancer: A prospective randomized trial. Proc Am Soc Clin Oncol 9:21,1990,  (abstr 77)"},{"key":"R27","unstructured":"Black MM, Speer FD: Nuclear structure in cancer tissues. Surg Gynecol Obstet 105:97,1957-102,"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2002.s.014"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.136"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19881215)62:12<2507::AID-CNCR2820621210>3.0.CO;2-D"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.93"},{"key":"R32","unstructured":"Buzdar AU, Valero V, Theriault RL, et al: Pathologic complete response to chemotherapy is related with hormone receptor status. Breast Cancer Res Treat 82:S69a,2003,  (suppl 1)"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008400706949"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1023\/A:1024333725148"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.005"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1053\/ejso.2002.1404"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/82.19.1539"},{"key":"R38","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1996.565"},{"key":"R39","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940815)74:4<1283::AID-CNCR2820740417>3.0.CO;2-S"},{"key":"R40","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.1800780228"},{"key":"R41","unstructured":"Dixon JM, Renshaw L, Bellamy C, et al: The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: A randomized, double-blind, single-center study. Clin Cancer Res 6:2229,2000-2235,"},{"key":"R42","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010669403283"},{"key":"R43","doi-asserted-by":"publisher","DOI":"10.1023\/A:1013128213451"},{"key":"R44","unstructured":"Smith I, Dowsett M, on behalf of the IMPACT trialists: Comparison of anastrozole vs. tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive breast cancer in postmenopausal women: The IMPACT trial. Breast Cancer Res Treat 82:S5,2003,  (suppl 1)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.03.111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T21:01:51Z","timestamp":1653512511000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.03.111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1,1]]}},"alternative-id":["10.1200\/JCO.2005.03.111"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.03.111","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,1]]}}}